UK markets open in 6 hours 6 minutes

Zymeworks Inc. (ZYME)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
5.48-0.14 (-2.49%)
At close: 04:00PM EDT
5.74 +0.26 (+4.74%)
After hours: 04:08PM EDT
Sign in to post a message.
  • V
    VISHN
    Is there any way to find out who the Top Institutional Holders of ZYME shares as of today? I don't think Yahoo is projecting correctly
  • S
    Sam
    what's this stock.. management get their big checks and bonuses. who cares about shareholder value.
    maybe the reason they rejected the offer was they were probably going get laid off..
  • a
    arthur
    l guess things are great we needed another chief scientist
  • A
    Alain
    Given the chance, Kenneth Galbraith will yet again destroy a promising biotech company.
    The guy is simply not trusted to know what he’s doing.
    He already destroyed Prometic under the same mandate of turning the company around, now he’s running this PUBLICLY traded company like a private boy’s club.
    His ties with Klompas seem to be the only credentials that got him hired at Zymeworks, and now he announces that Paul Moore, VP Cell biology and immunology at Macrogenics will join the team at ZYME. KG and Paul have a 14 year old tie at Macrogenics where Ken was a corporate director for 14 years.
    KG is not hiding anything from market regulators about the shady business he is running: Surpisingly hired as Prometic CEO to lead company turnaround, hires his friend Klompas as director, buys out a company he owned a few days prior (Fairhaven Pharmaceutical, with ProMetic’s funds), quits after 1.5 years claiming “personal reasons”, gets hired at Zymeworks (strong recommendation from Klompas?), rejects an offer to buy the company by All Blue for twice the destroyed value of shares citing he is doing that in the best interest of the company and its shareholders while he owns no shares, and now hired his acquaintance (good friend?) from Macrogenics where they’ve worked together for 14 years???

    I truly hope one of the institutions will pursue KG’s decision making by exposing it to the public.

    The man is not trusted, he is not invested, and only seems to care about himself and his friends at corporate level.

    His salary and position title seem to be what’s driving him. He needs to be stopped before he wrecks yet another company, and moves on to another one…
  • J
    JR
    If the institutional and mutual funds start unloading, this will crater quickly. Imagine holding over 5 million shares and watching this? At some point I would think they would take their losses and move on to better possibilities.
  • J
    JohnD
    JPM lowers pt to $14. I would be delighted if a new suitor emerged at that price. ASCO data seemed strong, but street has little confidence they can pull off a deal. Otherwise, big pharma will pick the bones on Zani and Z49 in a further fire sale in 2023. Clock is tickin Ken
  • a
    arthur
    So we all know that they are not looking out for us but protecting their jobs only . Because once there is a take over, they know they are going to be let go.
  • b
    betonme444
    If AB wants ZYME then AB will have to pay more than 2 billion dollars with the poison pill in effect. OH MY!
  • P
    Peter
    Never know what is happening in the background, but I wouldn't hold your breath for All Blue --- when the rubber hit the road All Blue has thus far shown they are not willing/capable of following through on their bid. In fact, as much as I have concerns with Zyme, they pretty much punked AB by calling AB's bluff. Not sure how anybody would take a letter from AB seriously in the future after this result (thus far).
    Hoping for the best for Zyme over the long term
  • b
    betonme444
    It makes sense to me not sell a company for 773 millions when you have 250 millions in the bank and blockbuster results around the corner. PAYIENCE!
  • P
    P19
    I think if AB come again even with the same 10.50 offer and say it’s binding and financed, I could it getting traction - or else just tender
  • S
    Selvam
    heard all blue bought options , if they want to buy the company why are they buying stock options for dec 15 calls? any idea anyone
  • A
    Alain
    I think that whoever is trying to save the company, in this case All Blue, needs to look into the hiring process that landed KG the top job at ZYME. Again, why would anyone hire him to do at ZYME the same job he did and failed miserably with Prometic (now Liminal)? Look into his history with his friend Neil Klompas, both at Prometic and ZYME, and maybe the bulb will light up. Is it a friend returning a favour by giving a friend a job, or was he the best application for the job? Who was the competition, and first of all, was the job even posted anywhere or did Neil simply put his hand up and say “I know someone perfect for this job”…
    Answers may help voiding the adoption of the poison pill, who will turn out to be only poisonous to ZYME itself…
  • J
    JohnD
    My Rank Ordering of Zyme’s Destructors of Value:

    (1) Former leader “Ali” who spent like a drunken sailor (how did that Chief People Officer” work out), while delaying and obfuscating results;
    (2) The Board is a close second by turning a blind eye to management’s failure, while letting investment bankers “help them” avoid a takeover last year at about 8x current share price
    (3) KG comes next, executing a brutally dilutive offering followed by a poison pill.

    Note to current employees: don’t drink the brown holiday punch, as there are reports of multiple turds in the punchbowl
  • .
    .
    An other Trudeau Company, in the Socialist Republic.
  • P
    P19
    What just happened with that unexplained 5% drop!!!
  • P
    Papa
    What's with the after hours action? Or is this just on minimum shares?
  • A
    Alain
    Kenneth Galbraith has nothing to do with the share price rise of late. On the contrary, the hopes of an activist taking over the company and booting Galbraith has been the catalyst for the rise.
    We will soon see what Galbraith can bring (if anything) to this company and its shareholders. Presentations on the 4, 6, and 8 of June with one-on-one meetings jun 8 and 9. His job is to “sell” the benefits of their drugs, find a partner or whatever.
    Cutting jobs, letting qualified people go and raising money at a discount to current share price value is not talent; it’s change. It proved catastrophic when he did that after joining Prometic in 2019. No success here either with that technique.
    Where he will be showcased or make the company collapse is during the one-on-one meetings on 8-9 Jun. that’s really his first test and I think shareholders of ZYME will find out pretty quickly if he has any clue of what he’s doing. A successful
    Partnership or deal with All Blue (or other) will either happen shortly after those meetings, or the share price and the company will continue its descent to the crapper. Next 2 weeks promise to be interesting…
  • A
    Alain
    If Kenneth Galbraith really cares about the company and its shareholders as he stated when Zymeworks rejected All Blue's $10.50/share bid to buy the company, he will use this weekend and next week's presentations and meetings to do a deal with someone (All Blue or anyone else at $10.50 or higher). I am repeating myself but Glabraith had the same role when hired with Prometic (now Liminal) in April 2019, just to leave the company in a despicable state in Nov 2020, one and a half year later. He stated that he was leaving for personal reasons, but really, we can all make our own conclusion as to what may have really happened.
    It takes a real leader to know when to let go. Are the institutions owning more than 90% of the company willing to see if it works out this time around with Ken, or do they want to save the company and its products along with their investment in pushing Ken out for someone qualified? All Blue's picked their side. I keep mentionning it but was anyone able to look into the hiring process that lead Zymeworks to hire Galbraith in the first place? Not sure that there's anything to do here with his qualifications. I'm not talking about his paper qualifications, I'm talking about his actual talent.
    Anyway, I truly believe that Ken has an opportunity to do the right thing with a buyer knocking at the door and not hiding how interested they are at taking over the company and making this work. Is he going to let that go by claiming that he can do better for the company and its shareholders? A look at what happened to Prometic will show you that no matter how good your products are, bad management can always screw it up and wipe off entire years of work and research into oblivion, never to be seen again. Some people hold the power of destruction, is Ken Galbraith one of them or is he the one going to free the company?
  • P
    P19
    AB needs to sweeten the offer, present to mgmt and then go direct to shareholders if no support from mgmt